Dr. Shah on the Potential Rationale for Selecting Ide-Cel Vs Cilta-Cel In Multiple Myeloma

Video

Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Nina Shah, MD, a hematologist and oncologist, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel (ide-cel; bb2121) and ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma.

It is possible that the myeloma armamentarium will gain 2 CAR T-cell therapies in the near future, says Shah. However, selecting between the therapies if both receive FDA approval could be challenging, Shah adds.

Without comparing trials, subtle differences between ide-cel and cilta-cel have been observed, says Shah. Findings from the phase 2 KarMMA trial demonstrated a 73% overall response rate (ORR) with ide-cel, whereas the results of the phase 1/2 CARTITUDE-1 trial demonstrated an ORR of 96.9% with cilta-cel. Both products appear to induce deep and durable responses, but additional follow-up with cilta-cel is needed, says Shah.

Additionally, the median onset of cytokine release syndrome (CRS) was 2 days with ide-cel compared with 7 days with cilta-cel, which makes the latter more unpredictable in terms of toxicity management, Shah explains. As such, some patients may be better suited for ide-cel vs cilta-cel, but more data are needed, concludes Shah.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.